Consommation de tabac chez les jeunes hommes suisses: quelles influences de l'armée?

Le tabac à priser, appelé "snuff" ou encore "chnouff", est la plus ancienne forme de tabac connue en Europe (1). Il aurait été importé en Europe en 1493 par un moine Franciscain voyageant avec Christophe Colomb au retour des Caraïbes (2). Le tabac à priser consiste en une fine poudre de tabac communément brune actuellement vendue dans de petites boîtes de métal rondes. Dans la suite du manuscrit nous utiliserons le terme snuff pour désigner le tabac à priser. Il fait partie d'un groupe de produits appelé "tabac sans fumée" (en anglais "smokeless tobacco") comprenant également la snus (« moist snuff » en anglais, tabac non- fermenté destiné à une absorption par la muqueuse orale à ne pas confondre avec la snuff), et le tabac à mâcher (feuilles de tabac broyées ou compacts mastiquées puis recrachées). La plupart des articles scientifiques publiés sur le tabac sans fumée concernent la snus car elle est largement consommée dans les pays nordiques (en Suède et en Norvège plus particulièrement) et dans certains milieux sportifs

Papillomavirus humain: que savent les jeunes? [Human papillomavirus: what do young people really know about it?]

It has been five years since the introduction of the HPV vaccination campagnes in Switzerland. Although a majority of young people age 16 to 20 have heard about the HPV, many false beliefs regarding this virus and its effects persist, and a lot of young people feel insufficiently informed about it. The surveyed population is conscious that the HPV is a sexually transmitted infection; however, more than 80% do not know that men can also be infected. Preventive information must be improved to target men too, in order that everybody understands that men, as well as women, are concerned by this infection. Medical consultations are the ideal setting to inform young people about the HPV

Evaluation of therapeutic enoxaparin in a pregnant population at a tertiary hospital

Therapeutic anticoagulation with enoxaparin in pregnancy is complex due to varying pharmacokinetics and the increasing prevalence of obesity. There is limited evidence to support current dosing and monitoring strategies of enoxaparin in this population.To describe the current practice in therapeutic anticoagulation in the pregnant population at a tertiary institution.A retrospective study of pregnant women on therapeutic enoxaparin between January 2007 and December 2011.Forty-four pregnant women requiring therapeutic anticoagulation were identified and divided into two groups, monitored with anti-factor Xa (AXA) concentrations and unmonitored. Fifty-five percent of monitored women were initiated on the recommended 1 mg/kg twice a day (bd) enoxaparin dose-strategy. Eighty-two percent of women were monitored; however, there was variability regarding the timing, frequency and subsequent dose adjustments from monitoring. Overall, as pregnancies progressed, there was both increasing dose adjustments and increasing frequency of monitoring. Fourteen women had a BMI over 30 kg/m(2) , and 13 of these women were monitored. Nine monitored obese women required doses less than 1 mg/kg/bd to maintain a therapeutic AXA level. Management appeared to be individualised. There were small numbers of toxicity events.Variation exists in dosing and monitoring practices for therapeutic enoxaparin in the pregnant population. Dosing obese patients using 1 mg/kg twice daily can lead to toxic AXA concentrations, and dose reductions are required to maintain a therapeutic range. A larger prospective study reviewing dose, AXA concentrations and outcome data is necessary to make dosing recommendations in this group

Progressive hearing loss in Fabry's disease: a case report

Fabry's disease is a chromosomal X-linked inherited disease, which causes a lack of the lysosomal alpha-galactosidase A enzyme leading to a cellular accumulation of glycosphingolipids. This accumulation leads to various clinical disorders, including inner ear lesions, with sensorineural hearing loss and dizziness. This article proposes to describe a clinical case of a patient suffering from Fabry's disease with inner ear associated problems and to review the literature focusing on this subject

Black Vulture Conflict and Management in the United States: Damage Trends, Management Overview, and Research Needs

Contrary to rapid declines of many vulture (Accipitridae, Cathartidea) species worldwide, black vulture (Coragyps atratus) populations are increasing and expanding their range in North America. Vultures exhibit complex behaviors and can adapt to any human-dominated landscape or land use. These traits, combined with population growth and range expansion, have contributed to increased human–vulture conflicts. Our goal was to summarize the current status and trends in human–black vulture conflicts (hereafter human–vulture conflicts), review available management strategies, identify knowledge gaps, and provide recommendations to enhance management and understanding of this species and the associated conflicts. We found human–vulture conflicts are increasing in agriculture (livestock), private and public property (both personal and infrastructure-based), and threats to human health and safety. The greatest increases in conflicts were reported in agriculture and private and public property damage. Regarding livestock depredation, good progress has been made toward assessing producer perceptions of the conflicts, including estimates of economic damage and mitigation strategies, but a basic understanding of the underlying mechanism driving the conflict and advancing strategies to mitigate damage is lacking. For damaged property, little information is available regarding economic losses and perceptions of stakeholders who are experiencing the damage, and most of the tools recommended for mitigating this damage have not been rigorously evaluated. Regarding human health and safety, recent research quantifying flight behavior of black vultures has direct implications for reducing aircraft collision risks. However, it is unclear what factors influence roost site selection and the most effective means to leverage the sensory ecology of the species to mitigate risks. We identify additional knowledge gaps and research needs that if addressed could increase managers’ understanding of black vulture ecology and facilitate enhanced management of this species while simultaneously allowing for the species to provide valuable ecosystem services

Non-severe aortic regurgitation increases short-term mortality in acute heart failure with preserved ejection fraction.

Mild or moderate aortic regurgitation (AR) has only little effect on cardiovascular outcome in people with normal left ventricular ejection fraction (EF); therefore, it is not perceived as a major clinical problem. This study investigates whether mild or moderate AR is associated with increased short-term mortality in patients hospitalized for treatment of acute heart failure (AHF) and whether mild or moderate AR impacts differently on short-term mortality in AHF patients with reduced EF (AHFrEF), mid-range EF (AHFmrEF), or preserved EF (AHFpEF). This mono-centric study included 505 consecutive adult patients hospitalized for de novo or worsening chronic HF not related to acute ischaemia or severe valvular pathology in the echocardiogram at index hospitalization. Cox regression analysis studied the impact of AR on all-cause mortality (ACM) over the 150 days' study period. Mild or moderate AR was associated with increased ACM (HR 1.75 [95% CI: 1.1-2.7]; P = 0.009). The prevalence of mild or moderate AR in the study population was 42% and not significantly different between AHFpEF (n = 227), AHFmrEF (n = 86), and AHFrEF (n = 192) study participants (37.9% vs. 50.0% vs. 42.7%; P = 0.144). In AHFpEF patients, the age-adjusted hazard for ACM was increased in patients with AR compared with patients without AR (HR 2.17 [95% CI: 1.1-4.2]; P = 0.002). The age-adjusted hazard for ACM was increased by a trend in AHFmrEF with AR (HR 7.11, [95% CI: 0.9-57.8]; P = 0.067) and not different between the AHFrEF groups (HR 0.95 [95% CI: 0.5-1.8]; P = 0.875). Mild or moderate AR increased ACM only in AHFpEF patients, highlighting a distinct clinical relevance

The Anticancer Peptide TAT-RasGAP317-326 Exerts Broad Antimicrobial Activity.

Antibiotic resistance has become a major health issue. Nosocomial infections and the prevalence of resistant pathogenic bacterial strains are rising steadily. Therefore, there is an urgent need to develop new classes of antibiotics effective on multi-resistant nosocomial pathogenic bacteria. We have previously shown that a cell-permeable peptide derived from the p120 Ras GTPase-activating protein (RasGAP), called TAT-RasGAP317-326, induces cancer cell death, inhibits metastatic progression, and sensitizes tumor cells to various anti-cancer treatments in vitro and in vivo. We here report that TAT-RasGAP317-326 also possesses antimicrobial activity. In vitro, TAT-RasGAP317-326, but not mutated or truncated forms of the peptide, efficiently killed a series of bacteria including Escherichia coli, Acinetobacter baumannii, Staphylococcus aureus, and Pseudomonas aeruginosa. In vivo experiments revealed that TAT-RasGAP317-326 protects mice from lethal E. coli-induced peritonitis if administrated locally at the onset of infection. However, the protective effect was lost when treatment was delayed, likely due to rapid clearance and inadequate biodistribution of the peptide. Peptide modifications might overcome these shortcomings to increase the in vivo efficacy of the compound in the context of the currently limited antimicrobial options

Termination Casts: A Flexible Approach to Termination with General Recursion

This paper proposes a type-and-effect system called Teqt, which distinguishes terminating terms and total functions from possibly diverging terms and partial functions, for a lambda calculus with general recursion and equality types. The central idea is to include a primitive type-form "Terminates t", expressing that term t is terminating; and then allow terms t to be coerced from possibly diverging to total, using a proof of Terminates t. We call such coercions termination casts, and show how to implement terminating recursion using them. For the meta-theory of the system, we describe a translation from Teqt to a logical theory of termination for general recursive, simply typed functions. Every typing judgment of Teqt is translated to a theorem expressing the appropriate termination property of the computational part of the Teqt term.Comment: In Proceedings PAR 2010, arXiv:1012.455

The TAT-RasGAP317-326 anti-cancer peptide can kill in a caspase-, apoptosis-, and necroptosis-independent manner.

Tumor cell resistance to apoptosis, which is triggered by many anti-tumor therapies, remains a major clinical problem. Therefore, development of more efficient therapies is a priority to improve cancer prognosis. We have previously shown that a cell-permeable peptide derived from the p120 Ras GTPase-activating protein (RasGAP), called TAT-RasGAP317-326, bears anti-malignant activities in vitro and in vivo, such as inhibition of metastatic progression and tumor cell sensitization to cell death induced by various anti-cancer treatments. Recently, we discovered that this RasGAP-derived peptide possesses the ability to directly kill some cancer cells. TAT-RasGAP317-326 can cause cell death in a manner that can be either partially caspase-dependent or fully caspase-independent. Indeed, TAT-RasGAP317-326-induced toxicity was not or only partially prevented when apoptosis was inhibited. Moreover, blocking other forms of cell death, such as necroptosis, parthanatos, pyroptosis and autophagy did not hamper the killing activity of the peptide. The death induced by TAT-RasGAP317-326 can therefore proceed independently from these modes of death. Our finding has potentially interesting clinical relevance because activation of a death pathway that is distinct from apoptosis and necroptosis in tumor cells could lead to the generation of anti-cancer drugs that target pathways not yet considered for cancer treatment